Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 16/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 2/20 | 0.38 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817593 | 0.88 | NR1H3 (0.46) | CYP11B1CYP11B2CPT1ACPT1BCYP2C9 | |
| SCHEMBL1818362 | 0.84 | PIK3CA (0.40) | CPT1ACPT1BCYP2C9 | |
| SCHEMBL1821637 | 0.84 | PKM (0.48) | CYP2C9 | |
| SCHEMBL1816941 | 0.83 | CYP2C9 (0.53) | CYP11B1CYP11B2CPT1ACPT1BCYP2C9 | |
| SCHEMBL1819206 | 0.83 | PKM (0.42) | CPT1ACPT1BCYP2C9 | |
| SCHEMBL1815092 | 0.82 | MEN1 (0.38) | CPT1ACPT1BCYP2C9 | |
| SCHEMBL1816305 | 0.82 | CYP2C9 (0.37) | CPT1ACPT1BCYP2C9 | |
| SCHEMBL1820266 | 0.82 | MEN1 (0.39) | CPT1ACPT1BCYP2C9 | |
| SCHEMBL1817317 | 0.80 | CYP2C9 (0.44) | CPT1ACPT1BCYP2C9 | |
| SCHEMBL1817603 | 0.80 | CYP2C9 (0.42) | CPT1ACPT1BCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057892-A1 | 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELARA PHARMACEUTICALS GMBH (DE) | 2011-05-19 | — | — | WO | claimed |
| WO-2011057892-A1 | 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELARA PHARMACEUTICALS GMBH (DE) | 2011-05-19 | — | — | WO | disclosed |